Successful Strategies for Mitigation of a Preclinical Signal for Phototoxicity in a DGAT1 Inhibitor

ACS Med Chem Lett. 2019 Jun 20;10(8):1128-1133. doi: 10.1021/acsmedchemlett.9b00117.

Tyler J Harrison ¹, Daniel Bauer ², Alina Berdichevsky ¹, Xin Chen ¹, Rohit Duvadie ¹, Benjamin Hoogheem ¹, Panos Hatsis ¹, Qian Liu ¹, Justin Mao ¹, Vasumathy Miduturu ¹, Erik Rocheford ¹, Frederic Zecri ¹, Richard Zessis ¹, Rui Zheng ¹, Qingming Zhu ¹, Ryan Streeper ¹, Sejal J Patel ¹

Affiliations

1 Global Discovery Chemistry, Cardiovascular and Metabolism, and PK Sciences, Novartis Institutes for Biomedical Research, 22 Windsor Street, Cambridge, Massachusetts 02139, United States.
2 Preclinical Safety, Novartis Institutes for Biomedical Research, 4002 Basel, Switzerland.

PMID: 31413796 DOI: 10.1021/acsmedchemlett.9b00117

Abstract

Diacylglycerol O-acyltransferase 1 (DGAT1) inhibitor Pradigastat (1) was shown to be effective at decreasing postprandial triglyceride levels in a patient population with familial chylomicronemia syndrome (FCS). Although pradigastat does not cause photosensitization in humans at the high clinical dose of 40 mg, a positive signal was observed in preclinical models of phototoxicity. Herein, we describe a preclinical phototoxicity mitigation strategy for diarylamine containing molecules utilizing the introduction of an amide or suitable heterocyclic function. This strategy led to the development of two second-generation compounds with low risk of phototoxicity, disparate exposure profiles, and comparable efficacy to 1 in a rodent lipid bolus model for post-prandial plasma triglycerides.

Name
Email *

	Sorry, but the email address you supplied was invalid.